Gisela Schwab - 21 Jul 2021 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role: Pres, Prod Dev & Med Aff & CMO
Signature: /s/ Jennifer Drimmer Rokovich, Attorney in Fact
Issuer symbol: EXEL
Transactions as of: 21 Jul 2021
Net transactions value: +$147,000
Form type: 4
Filing time: 23 Jul 2021, 19:47:51 UTC
Previous filing: 02 Jul 2021
Next filing: 28 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EXEL	Common Stock	Options Exercise	$147,000	+35,000	+5.7%	$4.20^*	649,078	21 Jul 2021	Direct	F1
holding	EXEL	Common Stock						14,880	21 Jul 2021	By 401(k)	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EXEL	Option (right to buy)	Options Exercise	$0	-35,000	-47%	$0.000000	40,000	21 Jul 2021	Common Stock	35,000	$4.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2	Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 20, 2021.
F3	The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.